The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results
Abstract
OBJECTIVE: Daclizumab is an interleukin 2 receptor alpha chain specific humanized monoclonal antibody that has shown promising therapeutic effects in multiple sclerosis (MS). Daclizumab treatment in patients with relapsing and remitting MS was administered to determine effects on MRI and clinical outcomes. METHODS: Patients with MS on interferon (IFN) therapy but with continuing relapses and contrast enhancing lesions (CEL) were selected. Patients were evaluated with monthly MRI scans and clinical rating scales starting 3 months prior to treatment and then at 0.5 to 27.5 months during treatment. Daclizumab (1 mg/kg IV) was administered twice in the first month (initiated and administered again in 2 weeks), followed by treatments every 4 weeks. IFN was continued until 5.5 months after daclizumab was initiated. Patients were then placed on daclizumab monotherapy. Patients with recurrent CEL were restarted on IFN with daclizumab therapy at (1.5 mg/kg IV) every 28 days. RESULTS: Nine patients qualified for inclusion and completed the trial. Efficacy measured by both total CEL and new CEL (p < 0.001), relapses, timed ambulation, Expanded Disability Status Scale, and Neurologic Rating Scale (p < 0.05 to p < 0.01) was observed. CONCLUSION: Daclizumab was effective in reducing contrast enhancing lesions and improving clinical scores in patients with relapsing and remitting multiple sclerosis with active disease not controlled by interferon therapy. These results provide evidence for long-term efficacy and support further clinical development of daclizumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Advances in interleukin 2 receptor targeted treatment
Morris, J. C., & Waldmann, T. A. (2000) · Annals of the Rheumatic Diseases · doi:10.1136/ard.59.suppl_1.i109 · Cited by 131
Cited by
The experimental autoimmune encephalomyelitis (EAE) model of MS
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52001-2.00008-x · Cited by 464
Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies
Wingerchuk, D. M., & Carter, J. L. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.11.002 · Cited by 416
Organ-specific features of natural killer cells
Shi, F.-D., Ljunggren, H.-G., La Cava, A., & Van Kaer, L. (2011) · Nature Reviews Immunology · doi:10.1038/nri3065 · Cited by 414
Wynn, D., Kaufman, M., Montalban, X., Vollmer, T., Simon, J., Elkins, J., O'Neill, G., Neyer, L., Sheridan, J., Wang, C., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70033-8 · Cited by 301
Self-citationWuest, S. C., Edwan, J. H., Martin, J. F., Han, S., Perry, J. S. A., Cartagena, C. M., Matsuura, E., Maric, D., Waldmann, T. A., & Bielekova, B. (2011) · Nature Medicine · doi:10.1038/nm.2365 · Cited by 284
Metadata
- Authors
- Rose, J. W., Burns, J. B., Bjorklund, J., Klein, J., Watt, H. E., & Carlson, N. G.
- Venue
- Neurology
- Published
- 2007-08-21
- Volume
- 69
- Issue
- 8
- Pages
- 785-789
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1984999645
- Cited by
- 161
- References
- 1
- FWCI
- 15.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. https://app.cochat.ai/papers/10.1212/01.wnl.0000267662.41734.1f
- The paper
- Rose, J. W., Burns, J. B., Bjorklund, J., Klein, J., Watt, H. E., & Carlson, N. G. (2007). Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology. https://doi.org/10.1212/01.wnl.0000267662.41734.1f
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.